Biotech Firm Hit With COVID-Related Derivative Suit Over Warrant Revisions
SAN FRANCISCO — An investor sued a biotechnology company’s board of directors and a hedge fund in California federal court on Sept. 17, alleging that the defendants breached their fiduciary duty...To view the full article, register now.
Already a subscriber? Click here to view full article